Gleevec and subsequent generation tyrosine kinase inhibitors are known to act at BCR-ABL and c-KIT sites that can regulate the response of the cerebrovasculature following brain injury (see Rossari et al., 2018, review). The gene discussed is BCR; the disease is injury.